Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 103-106

  Boronat, Anna ^a   Sepúlveda, María ^a   Llufriu, Sara ^a   Sabater, Lidia ^a   Blanco, Yolanda ^a   Gabilondo, Iñigo ^a   Solà, Nuria ^a   Villoslada, Pablo ^a   Dalmau, Josep ^b,c   Graus, Francesc ^a   Saiz, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoantibody; Cell based assay; Contactin 2; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

CONTACTIN 2 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELL ASSAY; CELL STRAIN HEK293; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; CONTACTIN 2; DISEASE PROGRESSION; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; YOUNG ADULT;

EID: 84857915056     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.023     Document Type: Article

References (21)

1. B receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011, 76:795-800.
2. Breij E.C.W., Brink B.P., Veerhuis R., van den Berg C., Vloet R., Yan R., Dijkstra C.D., van der Valk P., Bö L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63:16-25.
3. Derfuss T., Parikh K., Velhin S., Braun M., Mathey E., Krumbholz M., Kümpfel T., Moldenhauer A., Rader C., Sonderegger P., Pöllmann W., Tiefenthaller C., Bauer J., Lassmann H., Wekerle H., Karagogeos D., Hohlfeld R., Linington C. Contactin-2/TAG-1 directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8302-8307.
4. Derfuss T., Linington C., Hohlfeld R., Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J. Mol. Med. 2010, 88:753-761.
5. Di Pauli F., Mader S., Rostasy K., Schanda K., Bajer-Kornek B., Ehling R., Deisenhammer F., Reindl M., Berger T. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin. Immunol. 2011, 38:247-254.
6. Franciotta D., Salvetti M., Lolli F., Serafini B., Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008, 7:852-858.
7. Hauser, S.L., Waubant, E., Arnold, L.D., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., Langer-Gould, A., Smith, C.H., for the HERMES Trial Group B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
8. Irani R.S., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., Peles E., Buckley C., Lang B., Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
9. Jarius S., Franciotta D., Paul E., Ruprecht K., Bergamaschi R., Rommer P.S., Reuss R., Probst C., Kristoferitsch W., Wandinger K.P., Wildemann B. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders; frequency, origin, and diagnostic relevance. J. Neuroinflammation 2010, 7:1057-1065.
10. Lai M., Huijbers M.G.M., Lancaster E., Graus F., Bataller L., Balice-Gordon R., Cowell J.K., Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010, 9:776-785.
11. Lancaster E., Martínez-Hernández E., Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011, 77:179-189.
12. Lassmann H., Brück W., Luchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
13. Llufriu S., Pujol T., Blanco Y., Hankiewicz K., Squarcia M., Berenguer J., Villoslada P., Graus F., Saiz A. T2 hypointense rims and ring-enhancing lesions in MS. Mult. Scler. 2010, 16:1317-1325.
14. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., Al-Hayani A., Davies S.N., Rasband M.N., Olsson T., Moldenhauer A., Velhin S., Hohlfeld R., Meinl E., Linington C. Neurofascin as a novel target for autoantibody-mediated axonal injury. J. Exp. Med. 2007, 204:2363-2372.
15. Mike A., Glanz B.I., Hildenbrand P., Meier D., Bolden K., Liguori M., Dell'Oglio E., Healy B.C., Bakshi R., Guttmann C.R.G. Identification and clinical impact of multiple sclerosis cortical lesions assessed by routine 3T MR imaging. Am. J. Neuroradiol. 2011, 32:515-521.
16. + channels in myelinated axons depends on Caspr2 and TAG-1. J. Cell. Biol. 2003, 162:1149-1160.
17. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
18. Racke M.K. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 2008, 21(Suppl. 1):S9-S18.
19. Reindl M., Khalil M., Berger T. Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 2006, 180:50-62.
20. Savvaki M., Panagiotarapoulos T., Stamatakis A., Sargiannidou I., Karatzioula P., Watanabe K., Stylianopoulou F., Karagogeos D., Kleopa K.A. Impairment of learning and memory in TAG-1 deficient mice associated with shorter CNS internodes and disrupted juxtaparanodes. Mol. Cell. Neurosci. 2008, 39:478-490.
21. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:39-248.